Adenocarcinoma
MONDO:0004970A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.
Also known as: adenocarcinoma, adenocarcinoma NOS (morphologic abnormality), adenocarcinoma, malignant, adenocarcinoma, no subtype (morphologic abnormality), adenocarcinomas, ADNOS
7765 clinical trials for this condition and its sub-types, 186 tagged with Adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Adenocarcinoma
-
Hepatocellular carcinoma 1,046 trials · 1,091 incl. sub-types
8 sub-types
- Hepatoblastoma 42 trials Sub-types →
- Pediatric hepatocellular carcinoma 36 trials
- Fibrolamellar hepatocellular carcinoma 15 trials Sub-types →
- Adult hepatocellular carcinoma 12 trials
- Aflatoxin-related hepatocellular carcinoma 0 trials
- Hepatocellular clear cell carcinoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Sclerosing hepatic carcinoma 0 trials
-
Pancreatic adenocarcinoma 497 trials · 930 incl. sub-types
5 sub-types
- Pancreatic ductal adenocarcinoma 553 trials Sub-types →
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Pancreatic intraductal papillary-mucinous neoplasm with an associated invasive carcinoma 1 trial
- Mucinous pancreas adenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
-
Renal cell carcinoma 611 trials · 710 incl. sub-types
11 sub-types
- Renal cell adenocarcinoma 98 trials · 251 incl. sub-types Sub-types →
- Nonpapillary renal cell carcinoma 156 trials · 246 incl. sub-types Sub-types →
- Adrenal cortex carcinoma 42 trials Sub-types →
- Collecting duct carcinoma 18 trials
- Kidney medullary carcinoma 10 trials · 13 incl. sub-types Sub-types →
- MIT family translocation renal cell carcinoma 6 trials Sub-types →
- Wolffian duct adenocarcinoma 2 trials
- Acquired cystic disease-associated renal cell carcinoma 0 trials
- Cystic renal cell carcinoma 0 trials
- Mucinous tubular and spindle renal cell carcinoma 0 trials
- Renal pelvis adenocarcinoma 0 trials
-
Tubular adenocarcinoma 0 trials · 558 incl. sub-types
4 sub-types
- Pancreatic ductal adenocarcinoma 553 trials Sub-types →
- Invasive tubular breast carcinoma 5 trials
- Gastric tubular adenocarcinoma 0 trials
- Well-differentiated fetal adenocarcinoma of the lung 0 trials
-
Colorectal adenocarcinoma 247 trials · 548 incl. sub-types
5 sub-types
- Rectum adenocarcinoma 232 trials · 233 incl. sub-types Sub-types →
- Colon adenocarcinoma 90 trials · 121 incl. sub-types Sub-types →
- Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Colorectal serrated adenocarcinoma 1 trial
- Colorectal medullary carcinoma 0 trials Sub-types →
-
Gastroesophageal junction adenocarcinoma 507 trials
-
Gastric adenocarcinoma 449 trials · 481 incl. sub-types
9 sub-types
- Microinvasive gastric cancer 28 trials
- Diffuse gastric adenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Gastric cardia adenocarcinoma 4 trials
- Signet ring cell gastric adenocarcinoma 2 trials
- CTNNA1-related diffuse gastric and lobular breast cancer syndrome 0 trials
- Gastric intestinal type adenocarcinoma 0 trials
- Gastric papillary adenocarcinoma 0 trials
- Gastric tubular adenocarcinoma 0 trials
- Mucinous gastric adenocarcinoma 0 trials
-
Bile duct adenocarcinoma 17 trials · 419 incl. sub-types
1 sub-type
- Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types Sub-types →
-
Prostate adenocarcinoma 298 trials
2 sub-types
- Prostate adenoid cystic carcinoma 0 trials
- Prostatic acinar adenocarcinoma 0 trials Sub-types →
-
Breast adenocarcinoma 36 trials · 279 incl. sub-types
13 sub-types
- Breast ductal adenocarcinoma 19 trials · 192 incl. sub-types Sub-types →
- Breast lobular carcinoma 13 trials · 34 incl. sub-types Sub-types →
- Inflammatory breast carcinoma 29 trials
- Lobular breast carcinoma in situ 27 trials
- Mixed lobular and ductal breast carcinoma 1 trial Sub-types →
- Adenoid cystic breast carcinoma 0 trials
- Breast malignant eccrine spiradenoma 0 trials
- Breast mucinous cystadenocarcinoma 0 trials
- Mammary Paget disease 0 trials Sub-types →
- Mucoepidermoid breast carcinoma 0 trials
- Oncocytic breast carcinoma 0 trials
- Sebaceous breast carcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
-
Serous adenocarcinoma 6 trials · 242 incl. sub-types
6 sub-types
- Ovarian serous adenocarcinoma 199 trials · 203 incl. sub-types Sub-types →
- Fallopian tube serous adenocarcinoma 71 trials
- Peritoneal serous adenocarcinoma 2 trials · 39 incl. sub-types Sub-types →
- Endometrial serous adenocarcinoma 36 trials
- Serous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Cervical serous adenocarcinoma 0 trials Sub-types →
-
Ovarian adenocarcinoma 12 trials · 231 incl. sub-types
7 sub-types
- Ovarian serous adenocarcinoma 199 trials · 203 incl. sub-types Sub-types →
- Ovarian endometrioid adenocarcinoma 78 trials Sub-types →
- Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types Sub-types →
- Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types Sub-types →
- Ovarian cystadenocarcinoma 0 trials · 5 incl. sub-types Sub-types →
- Krukenberg carcinoma 1 trial
- Rete ovarii adenocarcinoma 0 trials
-
Clear cell adenocarcinoma 14 trials · 201 incl. sub-types
11 sub-types
- Clear cell renal carcinoma 140 trials · 142 incl. sub-types Sub-types →
- Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types Sub-types →
- Endometrial clear cell adenocarcinoma 21 trials
- Fallopian tube clear cell adenocarcinoma 18 trials
- Cervical clear cell adenocarcinoma 4 trials Sub-types →
- Bladder clear cell adenocarcinoma 1 trial Sub-types →
- Hidradenocarcinoma 1 trial Sub-types →
- Urethra clear cell adenocarcinoma 1 trial
- Extrahepatic bile duct clear cell adenocarcinoma 0 trials Sub-types →
- Glycogen-rich clear cell breast carcinoma 0 trials
- Hepatocellular clear cell carcinoma 0 trials
-
Esophageal adenocarcinoma 170 trials · 174 incl. sub-types
3 sub-types
- Barrett adenocarcinoma 6 trials
- Esophageal adenoid cystic carcinoma 0 trials
- Mucoepidermoid esophageal carcinoma 0 trials
-
Adenocarcinoma in situ 10 trials · 170 incl. sub-types
3 sub-types
- Ductal breast carcinoma in situ 152 trials Sub-types →
- Lobular breast carcinoma in situ 27 trials
- Lung adenocarcinoma in situ 1 trial
-
Endometrioid adenocarcinoma 13 trials · 146 incl. sub-types
6 sub-types
- Ovarian endometrioid adenocarcinoma 78 trials Sub-types →
- Endometrial endometrioid adenocarcinoma 56 trials Sub-types →
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Stage I endometrioid carcinoma 16 trials
- Stage II endometrioid carcinoma 2 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
-
Endometrium adenocarcinoma 30 trials · 119 incl. sub-types
9 sub-types
- Ovarian endometrioid adenocarcinoma 78 trials Sub-types →
- Endometrial clear cell adenocarcinoma 21 trials
- Endometrial mixed adenocarcinoma 10 trials
- Endometrial mucinous adenocarcinoma 2 trials
- Endometrial endometrioid adenocarcinoma with spindled epithelial cells 0 trials
- Mucin-rich endometrial endometrioid adenocarcinoma 0 trials
- Oxyphilic endometrial endometrioid adenocarcinoma 0 trials
- Secretory uterine corpus endometrioid adenocarcinoma 0 trials
- Villoglandular endometrial endometrioid adenocarcinoma 0 trials
-
Thyroid gland adenocarcinoma 0 trials · 118 incl. sub-types
3 sub-types
- Thyroid gland follicular carcinoma 20 trials · 77 incl. sub-types Sub-types →
- Thyroid gland papillary carcinoma 59 trials · 60 incl. sub-types Sub-types →
- Thyroid gland mucoepidermoid carcinoma 0 trials
-
Lung adenocarcinoma 114 trials · 117 incl. sub-types
11 sub-types
- Minimally invasive lung adenocarcinoma 9 trials Sub-types →
- Lung adenocarcinoma in situ 1 trial
- Lung signet ring cell carcinoma 1 trial
- Acinar lung adenocarcinoma 0 trials
- Lung adenoid cystic carcinoma 0 trials
- Lung colloid adenocarcinoma 0 trials Sub-types →
- Lung combined type small cell adenocarcinoma 0 trials
- Lung occult adenocarcinoma 0 trials
- Papillary lung adenocarcinoma 0 trials
- Solid adenocarcinoma with mucin production 0 trials
- Well-differentiated fetal adenocarcinoma of the lung 0 trials
-
Gastroesophageal adenocarcinoma 93 trials
-
Papillary adenocarcinoma 2 trials · 93 incl. sub-types
11 sub-types
- Thyroid gland papillary carcinoma 59 trials · 60 incl. sub-types Sub-types →
- Papillary renal cell carcinoma 26 trials · 28 incl. sub-types Sub-types →
- Ovarian serous surface papillary adenocarcinoma 2 trials
- Breast papillary carcinoma 1 trial Sub-types →
- Papillary eccrine carcinoma 1 trial Sub-types →
- Fallopian tube papillary adenocarcinoma 0 trials
- Gallbladder papillary neoplasm with an associated invasive carcinoma 0 trials
- Gastric papillary adenocarcinoma 0 trials
- Papillary cystadenocarcinoma 0 trials Sub-types →
- Papillary lung adenocarcinoma 0 trials
- Papillary thymic adenocarcinoma 0 trials
-
Fallopian tube adenocarcinoma 4 trials · 81 incl. sub-types
5 sub-types
- Fallopian tube serous adenocarcinoma 71 trials
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Fallopian tube clear cell adenocarcinoma 18 trials
- Fallopian tube mucinous adenocarcinoma 9 trials
- Fallopian tube papillary adenocarcinoma 0 trials
-
Small intestine adenocarcinoma 18 trials · 60 incl. sub-types
2 sub-types
- Duodenal adenocarcinoma 9 trials · 44 incl. sub-types Sub-types →
- Jejunal adenocarcinoma 0 trials
-
Mucinous adenocarcinoma 18 trials · 57 incl. sub-types
17 sub-types
- Colon mucinous adenocarcinoma 2 trials · 21 incl. sub-types Sub-types →
- Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types Sub-types →
- Fallopian tube mucinous adenocarcinoma 9 trials
- Mucinous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Endometrial mucinous adenocarcinoma 2 trials
- Mucoepidermoid carcinoma 2 trials Sub-types →
- Breast mucinous carcinoma 1 trial Sub-types →
- Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Rectum mucinous adenocarcinoma 1 trial Sub-types →
- Acinar prostate mucinous adenocarcinoma 0 trials
- Colloid carcinoma of the pancreas 0 trials
- Extrahepatic bile duct mucinous adenocarcinoma 0 trials Sub-types →
- Gallbladder mucinous adenocarcinoma 0 trials
- Lung colloid adenocarcinoma 0 trials Sub-types →
- Mucinous gastric adenocarcinoma 0 trials
- Mucinous pancreas adenocarcinoma 0 trials
- Salivary gland mucinous adenocarcinoma 0 trials
-
Adenoid cystic carcinoma 47 trials · 48 incl. sub-types
17 sub-types
- Paranasal sinus adenoid cystic carcinoma 5 trials Sub-types →
- Salivary gland adenoid cystic carcinoma 3 trials Sub-types →
- Bartholin gland adenoid cystic carcinoma 0 trials
- Adenoid cystic breast carcinoma 0 trials
- Adenoid cystic carcinoma of oropharynx 0 trials
- Adenoid cystic carcinoma of the corpus uteri 0 trials
- Cervical adenoid cystic carcinoma 0 trials
- Cutaneous adenocystic carcinoma 0 trials
- Esophageal adenoid cystic carcinoma 0 trials
- Lacrimal gland adenoid cystic carcinoma 0 trials
- Laryngeal adenoid cystic carcinoma 0 trials
- Lung adenoid cystic carcinoma 0 trials
- Lymph node adenoid cystic carcinoma 0 trials
- Pharyngeal adenoid cystic carcinoma 0 trials
- Prostate adenoid cystic carcinoma 0 trials
- Tracheal adenoid cystic carcinoma 0 trials
- Vaginal adenoid cystic carcinoma 0 trials
-
Cervical adenocarcinoma 27 trials · 34 incl. sub-types
10 sub-types
- Cervical adenosquamous carcinoma 16 trials Sub-types →
- Cervical clear cell adenocarcinoma 4 trials Sub-types →
- Endocervical adenocarcinoma 3 trials
- Wolffian duct adenocarcinoma 2 trials
- Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Cervical adenoid cystic carcinoma 0 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
- Cervical serous adenocarcinoma 0 trials Sub-types →
- Early invasive cervical adenocarcinoma 0 trials
- Uterine ligament adenocarcinoma 0 trials Sub-types →
-
Acinar cell carcinoma 4 trials · 15 incl. sub-types
5 sub-types
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Acinic cell breast carcinoma 0 trials
- Parotid gland acinic cell carcinoma 0 trials
- Prostatic acinar adenocarcinoma 0 trials Sub-types →
- Salivary gland acinic cell carcinoma 0 trials
-
Signet ring cell carcinoma 4 trials · 11 incl. sub-types
11 sub-types
- Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Signet ring cell gastric adenocarcinoma 2 trials
- Krukenberg carcinoma 1 trial
- Lung signet ring cell carcinoma 1 trial
- Acinar prostate adenocarcinoma, signet ring variant 0 trials
- Bladder signet ring cell adenocarcinoma 0 trials
- Extrahepatic bile duct signet ring cell carcinoma 0 trials Sub-types →
- Gallbladder signet ring cell adenocarcinoma 0 trials
- Pancreatic signet ring cell adenocarcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
- Signet ring cell variant cervical mucinous adenocarcinoma 0 trials
-
Gallbladder adenocarcinoma 9 trials
4 sub-types
-
Paget disease 2 trials · 9 incl. sub-types
5 sub-types
- Extramammary Paget disease 7 trials Sub-types →
- Cutaneous Paget disease 0 trials · 1 incl. sub-types Sub-types →
- Mammary Paget disease 0 trials Sub-types →
- Osteosarcoma arising in bone Paget disease 0 trials
- Scrotum Paget disease 0 trials
-
Bladder adenocarcinoma 5 trials · 8 incl. sub-types
7 sub-types
- Bladder urachal adenocarcinoma 5 trials
- Bladder clear cell adenocarcinoma 1 trial Sub-types →
- Bladder mixed adenocarcinoma 1 trial
- Bladder colloid adenocarcinoma 0 trials
- Bladder colonic type adenocarcinoma 0 trials
- Bladder hepatoid adenocarcinoma 0 trials
- Bladder signet ring cell adenocarcinoma 0 trials
-
Vaginal adenocarcinoma 7 trials
1 sub-type
- Vaginal adenoid cystic carcinoma 0 trials
-
Diffuse type adenocarcinoma 1 trial · 6 incl. sub-types
1 sub-type
- Diffuse gastric adenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
-
Cystadenocarcinoma 0 trials · 6 incl. sub-types
6 sub-types
- Mucinous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Ovarian cystadenocarcinoma 0 trials · 5 incl. sub-types Sub-types →
- Serous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Biliary cystadenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
- Papillary cystadenocarcinoma 0 trials Sub-types →
-
Vulvar adenocarcinoma 3 trials · 5 incl. sub-types
7 sub-types
- Vulval Paget disease 2 trials
- Bartholin gland adenocarcinoma 0 trials Sub-types →
- Adenocarcinoma of skene gland origin 0 trials
- Vulvar apocrine adenocarcinoma 0 trials
- Vulvar clear cell hidradenocarcinoma 0 trials
- Vulvar eccrine adenocarcinoma 0 trials Sub-types →
- Vulvar sebaceous carcinoma 0 trials
-
Parathyroid gland carcinoma 4 trials
-
Pituitary adenocarcinoma 3 trials
3 sub-types
-
Sebaceous adenocarcinoma 2 trials · 3 incl. sub-types
3 sub-types
- Ocular sebaceous carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Sebaceous breast carcinoma 0 trials
- Vulvar sebaceous carcinoma 0 trials
-
Hepatoid adenocarcinoma 2 trials
1 sub-type
- Bladder hepatoid adenocarcinoma 0 trials
-
Mesonephric adenocarcinoma 2 trials
1 sub-type
- Wolffian duct adenocarcinoma 2 trials
-
Sweat gland carcinoma 1 trial · 2 incl. sub-types
4 sub-types
- Apocrine adenocarcinoma 2 trials Sub-types →
- Eccrine carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Hidradenocarcinoma 1 trial Sub-types →
- Cutaneous adenocystic carcinoma 0 trials
-
Urethra adenocarcinoma 1 trial · 2 incl. sub-types
1 sub-type
-
Micropapillary serous carcinoma 1 trial
-
Nasal cavity adenocarcinoma 1 trial
-
Seminal vesicle adenocarcinoma 1 trial
-
Trabecular adenocarcinoma 1 trial
-
Ureter adenocarcinoma 1 trial
-
Adenoacanthoma 0 trials
-
Epididymal adenocarcinoma 0 trials
-
Ethmoid sinus adenocarcinoma 0 trials
-
Granular cell carcinoma 0 trials
-
Intestinal type adenocarcinoma 0 trials
2 sub-types
-
Lacrimal gland adenocarcinoma 0 trials
2 sub-types
-
Maxillary sinus adenocarcinoma 0 trials
-
Middle ear adenocarcinoma 0 trials
-
Minor salivary gland adenocarcinoma 0 trials
1 sub-type
-
Rete testis adenocarcinoma 0 trials
-
Scirrhous adenocarcinoma 0 trials
-
Submandibular gland adenocarcinoma 0 trials
-
Thymus gland adenocarcinoma 0 trials
2 sub-types
- Papillary thymic adenocarcinoma 0 trials
- Thymic mucoepidermoid carcinoma 0 trials
-
Villous adenocarcinoma 0 trials
2 sub-types
Most studied deeper sub-types
-
Targeted antibody zolbetuximab tested with chemo against advanced stomach cancer
Disease control Not yet recruitingResearchers are testing whether adding zolbetuximab to standard chemotherapy is safe and helps control advanced stomach or gastroesophageal junction cancer in Indian patients. The trial enrolls 50 adults whose tumors carry the Claudin 18.2 protein but not HER2. Participants recei…
Phase 4 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
New vaccine combo aims to halt prostate cancer growth without surgery
Disease control Not yet recruitingThis phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Can a new drug boost immunotherapy against Hard-to-Treat stomach cancer?
Disease control Not yet recruitingResearchers are testing whether adding an experimental drug called ONO-4578 to nivolumab and chemotherapy helps people with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal adenocarcinoma. The trial enrolls about 600 adults whose tumors are HE…
Phase 3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can adding chemo after radiation help older adults with rectal cancer avoid surgery?
Disease control Not yet recruitingThis phase 3 trial is testing whether adding a three-month course of FOLFOX4s chemotherapy after short-course radiotherapy improves outcomes compared to radiotherapy alone in adults aged 75 and older with locally advanced rectal cancer. The study aims to see if the combination ca…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Virtual cooking classes aim to boost health for hispanic prostate cancer survivors and their families
Disease control Not yet recruitingThis study tests whether a 12-week virtual cooking and nutrition program is practical and helpful for Hispanic prostate cancer survivors and their caregivers. Participants attend nutrition education, cooking classes, and health coaching sessions online. The goal is to see if the …
Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Targeted drug combo aims to tackle tough stomach cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—becotatugvedotin (a targeted therapy that delivers a toxin directly to cancer cells) and pucotenlimab (an immunotherapy that helps the immune system attack cancer)—as a second-line treatment for people with advanced gastric or g…
Phase 2 • Sponsor: West China Second University Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan (Sac-TMT) and fruquintinib—as a second-line treatment for people with advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after initial therapy. The study enrolls about 45 par…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Vitamin d trial aims to strengthen immune system in black men with prostate cancer
Disease control Not yet recruitingThis phase 3 trial tests whether daily vitamin D supplements can improve immune function and quality of life in Black/West African men with prostate cancer who have low vitamin D levels. Researchers will compare men with localized disease to those with advanced cancer, tracking i…
Phase 3 • Sponsor: University of Ilorin Teaching Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Not yet recruitingThis phase 2 trial tests whether adding mevrometostat to enzalutamide can slow cancer growth in 60 men with metastatic castration-resistant prostate cancer who have already been treated with similar drugs. Participants will take both drugs orally. The main goal is to see how long…
Phase 2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Smarter radiation aims to cut side effects in prostate cancer relapse
Disease control Not yet recruitingThis study tests a personalized radiation approach for men whose prostate cancer has returned after surgery. Using PSMA PET scans, doctors will give higher radiation doses to active cancer spots and lower doses to healthy areas, all in just 5 treatments over two weeks. The goal i…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail aims to keep prostate cancer away after surgery
Disease control Not yet recruitingThis study tests whether the drug rezvilutamide, combined with standard hormone therapy, can prevent high-risk prostate cancer from coming back after surgical removal. About 33 participants will take the pills and get injections for up to 2 years. The main goal is to see how many…
Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug cocktail aims to stop cervical cancer return
Disease control Not yet recruitingThis phase II trial tests whether adding pembrolizumab and lenvatinib to standard chemoradiation and brachytherapy can improve outcomes for adults with high-risk locally advanced cervical cancer. About 87 participants will receive the drug combination and be followed for two year…
Phase 2 • Sponsor: Prof. Dr. Remi A. Nout • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could surgery after hormone therapy beat advanced prostate cancer?
Disease control Not yet recruitingThis study looks at men with advanced prostate cancer that has spread to other parts of the body. After 6 months of hormone therapy, those whose scans show the cancer is well-controlled may either continue hormone therapy alone or also have their prostate removed. The goal is to …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
A sharper eye on prostate cancer: could new imaging spare healthy tissue?
Diagnosis Not yet recruitingThis pilot study is testing whether a special PET/MRI scan using a radioactive tracer called 68Ga-PSMA-11 can better identify all areas of significant prostate cancer in men with localized disease. The goal is to improve selection for focal therapy, a treatment that targets only …
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
Prostate cancer Treatment's hidden cost: study tracks sexual side effects
Symptom relief Not yet recruitingThis study follows 130 men with unfavorable intermediate-risk prostate cancer to see how a combination of targeted radiation (SBRT) and 6 months of hormone therapy (ADT) impacts their sexual function. Researchers measure erectile function before treatment and again after 24 month…
Sponsor: CancerCare Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can Real-World data reveal the best rectal cancer treatment?
Knowledge-focused Not yet recruitingThis observational study gathers information from routine care on how localized rectal cancer is treated across Austrian hospitals. It aims to document the variety of treatment approaches, including total neoadjuvant therapy and immunotherapy, and their outcomes. By analyzing thi…
Sponsor: Austrian Breast & Colorectal Cancer Study Group • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Mapping Real-World care for stomach cancer in greece
Knowledge-focused Not yet recruitingThis observational study tracks how patients with stage II to IVB gastric or gastroesophageal junction cancer are actually treated in routine clinical practice across Greece. Researchers will collect data on patient characteristics, treatment choices, timing of therapies, and bio…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Blood test may predict stomach cancer return after surgery
Knowledge-focused Not yet recruitingThis study looks at whether a simple blood test can help doctors decide the best treatment after surgery for stomach or gastroesophageal junction cancer. About 32 people with stage III or IVA cancer will give blood samples before and after surgery to check for tumor DNA. The goal…
Phase 2 • Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Genetic risk profiles could change how we monitor Barrett's esophagus
Knowledge-focused Not yet recruitingThis study looks at whether sharing genetic risk information with Barrett's esophagus patients can improve their quality of life and reduce cancer worry. Researchers will collect tissue samples and use genetic analysis to create risk profiles. Half of the 266 participants will le…
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC